Trial Profile
A Phase II Study of Neoadjuvant Lapatinib Plus Chemotherapy (Sequential FEC75 and Paclitaxel) in Women With Inflammatory Breast Cancer Whose Tumors Overexpress ErbB2 (Her2/Neu).
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 03 Jul 2023
Price :
$35
*
At a glance
- Drugs Lapatinib (Primary) ; Cyclophosphamide; Epirubicin; Fluorouracil; Paclitaxel
- Indications Breast cancer
- Focus Therapeutic Use
- 03 Nov 2014 Status changed from completed to discontinued as reported by ClinicalTrials.gov record.
- 10 Oct 2013 Status changed from active, no longer recruiting to discontinued as reported by M.D. Anderson Cancer Center.
- 01 Oct 2013 Status changed from discontinued to completed as reported by ClinicalTrials.gov.